Home › Compare › CTXRW vs NNN

CTXRW vs NNN: Dividend Comparison 2026

CTXRW yields 1387.93% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTXRW wins by $346908156.07M in total portfolio value
10 years
CTXRW
CTXRW
● Live price
1387.93%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$346908156.10M
Annual income
$303,843,436,712,884.44
Full CTXRW calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — CTXRW vs NNN

📍 CTXRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTXRWNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTXRW + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CTXRW pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTXRW
Annual income on $10K today (after 15% tax)
$117,973.63/yr
After 10yr DRIP, annual income (after tax)
$258,266,921,205,951.75/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, CTXRW beats the other by $258,266,921,203,722.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTXRW + NNN for your $10,000?

CTXRW: 50%NNN: 50%
100% NNN50/50100% CTXRW
Portfolio after 10yr
$173454078.06M
Annual income
$151,921,718,357,753.56/yr
Blended yield
87.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

CTXRW
No analyst data
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTXRW buys
0
NNN buys
0
No recent congressional trades found for CTXRW or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTXRWNNN
Forward yield1387.93% ✓5.66%
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$346908156.10M ✓$25.5K
Annual income after 10y$303,843,436,712,884.44 ✓$2,622.67
Total dividends collected$343747776.19M ✓$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CTXRW vs NNN ($10,000, DRIP)

YearCTXRW PortfolioCTXRW Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$149,493$138,792.51$10,735$614.96+$138.8K → CTXRW
2$2,099,063$1,939,106.48$11,572$708.43+$2.09M → CTXRW
3$27,692,262$25,446,263.94$12,531$819.53+$27.68M → CTXRW
4$343,373,046$313,742,325.46$13,633$952.29+$343.36M → CTXRW
5$4,003,185,043$3,635,775,884.26$14,909$1,111.84+$4003.17M → CTXRW
6$43,897,781,482$39,614,373,485.65$16,392$1,304.77+$43897.77M → CTXRW
7$452,951,824,425$405,981,198,239.62$18,129$1,539.52+$452951.81M → CTXRW
8$4,399,656,810,870$3,914,998,358,735.43$20,173$1,827.08+$4399656.79M → CTXRW
9$40,247,401,294,059$35,539,768,506,427.31$22,597$2,181.81+$40247401.27M → CTXRW
10$346,908,156,097,527$303,843,436,712,884.44$25,491$2,622.67+$346908156.07M → CTXRW

CTXRW vs NNN: Complete Analysis 2026

CTXRW — Stock

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Full CTXRW Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this CTXRW vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTXRW vs SCHDCTXRW vs JEPICTXRW vs OCTXRW vs KOCTXRW vs MAINCTXRW vs ADCCTXRW vs EPRTCTXRW vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.